Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS To Acquire ZymoGenetics | Contract Pharma

What are you searching for?

Sign in
Breaking News

BMS To Acquire ZymoGenetics

Bristol-Myers Squibb Co. has agreed to acquire ZymoGenetics, Inc. for $735 million, adding biologics for hepatitis and other diseases to its pipeline.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb Co. has agreed to acquire ZymoGenetics, Inc. for $735 million, adding biologics for hepatitis and other diseases to its pipeline. The acquisition is part of the company’s strategy to expand its virology franchise, as well as an effort to offset expected loss of market exclusivity in the next few years for top-selling drugs, namely Plavix.

Bristol-Myers Squibb chief executive officer Lamberto Andreotti said, “The acquisition gives the company full ownership of a promising investigational biologic that strengthens our very diversified hepatitis C portfolio.” The two companies have collaborated on development of pegylated-interferon lambda since January 2009. The product is now in Phase II trials.

ZymoGenetics’ other products include Recothrom, a drug for use in surgery to prevent blood clotting; IL-21 protein in Phase II development as a potential immunotherapy treatment for metastatic melanoma; and six biologic drug candidates for atopic dermatitis. ZymoGenetics also is in six partnered programs with Merck KGaA affiliate EMD Serono Inc. and Novo Nordisk A/S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters